European Commission approval adds an oral Wegovy option: a once-daily oral semaglutide 25 mg for adults with obesity or overweight plus at least one weight-related comorbidity. The regulatory green light is a positive expansion of the franchise and potential market reach versus an injectables-only profile.
European Commission approval adds an oral Wegovy option: a once-daily oral semaglutide 25 mg for adults with obesity or overweight plus at least one weight-related comorbidity. The regulatory green light is a positive expansion of the franchise and potential market reach versus an injectables-only profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
